Results of observational study published in Genetics in Medicine
The research team conducted an observational study of participants enrolled in MyCode, which returns medically actionable results, including an individual’s increased genetic risk for hereditary breast and ovarian cancers, Lynch syndrome and familial hypercholesterolemia. These conditions are among those recognized by the Centers for Disease Control and Prevention as having “tier 1” evidence for interventions that reduce morbidity and mortality in people with increased genetic risk.
The team found that 87 percent of study participants with a tier 1 gene variant did not have a prior diagnosis of the related condition. More than 70 percent of individuals who were notified of their genetic result then had a recommended procedure, such as a colonoscopy or lipid panel, following the notification. This evidence suggests that genomic screening programs are an effective way to identify individuals who could benefit from early intervention and risk management but have not yet been diagnosed, and encourage these individuals to take measures to reduce their risk, researchers said.
Results of the study were published in Genetics in Medicine.
“This study shows that genomic screening can identify at-risk individuals more comprehensively than previous methods and start people on the path to managing that risk,” said Adam Buchanan, director of Geisinger’s Genomic Medicine Institute. “The next step is figuring out the impact genomic screening has on improving population health.”
Geisinger’s MyCode precision medicine project has enrolled more than 265,000 participants in Pennsylvania and New Jersey. With DNA sequence and health data currently available on nearly 145,000 of these participants, MyCode is the largest study of its kind in the world.
MyCode analyzes DNA samples to look for genes known to increase the risk of developing 35 specific health conditions, including the BRCA1 and BRCA2 genes known to increase risk for breast and ovarian cancer; genes for familial hypercholesterolemia, which can cause early heart attacks and strokes; Lynch syndrome, which can cause early colon, uterine and other cancers; and several heart conditions, including cardiomyopathy and arrhythmia. In all, MyCode has returned medically actionable results to more than 1,500 patients.
For more information on MyCode or to enroll, visit geisinger.org/mycode.
Geisinger is committed to making better health easier for the more than 1 million people it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 10 hospital campuses, a health plan with more than half a million members, a research institute and the Geisinger College of Health Sciences, which includes schools of medicine, nursing and graduate education. With more than 25,000 employees and 1,700+ employed physicians, Geisinger boosts its hometown economies in Pennsylvania by billions of dollars annually. Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.
For media inquiries:
Ashley Andyshak Hayes
Marketing & Communications